1207452-66-1

Basic information

• Product Name: 8,9-bis(4-((methylamino)methyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
• Synonyms: 8,9-bis(4-((methylamino)methyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
• CAS NO: 1207452-66-1
• Molecular Weight: 425.533
• Mol File: 1207452-66-1.mol

Chemical Properties

• CAS DataBase Reference: 8,9-bis(4-((methylamino)methyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8,9-bis(4-((methylamino)methyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one(1207452-66-1)
• EPA Substance Registry System: 8,9-bis(4-((methylamino)methyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one(1207452-66-1)

Safety Data

• Hazardous Substances Data: 1207452-66-1(Hazardous Substances Data)

Upstream product

• 65399-18-0 4-nitrophthalide 
• 1207452-69-4 8,9-bis(4-(diethoxymethyl)phenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 1207452-67-2 methyl 2,3-bis(4-(diethoxymethyl)phenyl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 59434-19-4 4-Amino-1(3H)-isobenzofuranon 
• 81172-89-6 terephthalaldehyde mono(diethylacetal) 
• 593-77-1 N-Methylhydroxylamine 
• 1207452-70-7 4,4'-(3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazine-8,9-diyl)dibenzaldehyde 
• 623-27-8 terephthalaldehyde, 
• 641-70-3 3-nitrophthalic acid anhydride 
• 74-89-5 methylamine 

Relevant articles and documents

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.